Moderna, Inc. (NASDAQ:MRNA) today announced that the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK has granted marketing authorization for mRESVIA (mRNA-1345), indicated for ...
Vietnam Investment Review on MSN4d
AIM Vaccine's mRNA Shingles Vaccine Approved by the US FDA to Begin Clinical Trials, AI-Enabled mRNA Major Vaccine Product Development AcceleratesAIM Vaccine Co., Ltd. (06660.HK), a leading PRC vaccine company, published an announcement on March 23, 2025, the company's independently developed mRNA shingles vaccine has recently received clinical ...
GlobalData on MSN2d
FDA fast tracks Sanofi’s mRNA vaccine for chlamydiaSanofi will soon commence a Phase I/II trial with its vaccine candidate to start generating immunogenicity data.
With AI support, AIM is expected to rapidly advance multiple key products, including the mRNA shingles vaccine, mRNA RSV vaccine, and mRNA influenza vaccine. Previously, the research report from Fosun ...
designed to protect against RSV and COVID-19. Beyond vaccines, pharma is looking to develop mRNA vaccines to treat diseases requiring protein expression, such as cancer. Cancer has proved to be a ...
GSK has filed a pair of lawsuits against Moderna, claiming infringement of patents covering mRNA vaccines for COVID-19 and respiratory syncytial virus (RSV). According to court documents ...
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.
As a result of the recognition of the increased impact of these viruses, new vaccines and therapeutic options have been and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback